Anti-Viral Therapies Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Anti-Viral Therapies Market covers analysis by Type (Generic Drugs and Branded Drugs), Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), and Application (HIV, Hepatitis, Virus Influenza, Herpes, and Other Applications), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00012650
  • Category : Pharmaceuticals
  • Status : Upcoming
  • No. of Pages : 170
Buy Now

The global anti-viral therapies market is expected to grow from US$ 47,228.91 million in 2021 to US$  82,928.76 million in 2028; it is estimated to grow at a CAGR of 8.4% from 2022 to 2031.

Anti-viral therapies involve the development of a treatment for viral infections. There are several strategies used to develop anti-viral therapy, including direct-acting anti-virals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize circulating viruses; and drugs that target cellular proteins or processes essential for viral replication.

The anti-viral therapies market is attributed to the increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials. However, the high cost of drug development is hampering the growth of the market.

The anti-viral therapies market is segmented on the basis of type, application, mechanism of action, and geography. The report offers insights and in-depth analysis of the anti-viral therapies market, emphasizing various parameters such as market trends, technological advancements, and market dynamics, as well as the competitive landscape analysis of leading market players.

Lucrative Regions of Anti-Viral Therapies Market

Lucrative Regions of Anti-Viral Therapies Market

Market Insights

Increasing R&D Expenditures in Pharmaceutical Companies Bolsters Anti-Viral Therapies Market Growth

Research and development (R&D) is an essential part of a company’s business. Pharmaceutical companies focus on R&D to introduce new drugs with enhanced medical and commercial potential. These companies invest majorly in R&D activities with an aim to deliver high-quality and innovative products in the market.

R&D Investments by Major Pharmaceutical Companies

R&D Investments by Major Pharmaceutical Companies

 

Note: Current conversion rate is considered.

Source: Annual Reports and The Insight Partners Analysis

R&D spending by the biopharmaceutical companies has increased over the years. According to the report of the Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of biopharmaceutical companies increased from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015. In the fiscal year 2014–2015, 16 pharmaceutical companies were among the world’s top 50 companies in terms of total R&D investment. Novartis, Roche, Johnson & Johnson, and Pfizer are among the top 10 leading R&D investing companies globally. Further, in 2021, Astellas Pharma invested US$ 1803.70 million in the R&D of new and advanced drugs. Thus, an increase in R&D expenditure is anticipated to drive the anti-viral therapies market during the forecast period.

Type-Based Insights

Based on type, the anti-viral therapies market is bifurcated into generic drugs and branded drugs. The branded drugs segment held a larger share of the market in 2021; however, the generic drugs segment is anticipated to register a higher CAGR during the forecast period.

                                                             

Anti-Viral Therapies Market, by Type – 2021 and 2028

Anti-Viral Therapies Market, by Type – 2021 and 2028

Mechanism of Action-Based Insights

Based on mechanism of action, the anti-viral therapies market is segmented into nucleotide polymerase inhibitor, reverse transcriptase inhibitors, protease inhibitors, and others. The nucleotide polymerase inhibitor segment held the largest share of the market in 2021; also, the reverse transcriptase inhibitors segment is anticipated to register the highest CAGR in the market during the forecast period due to its effectiveness in reducing the spread of viral infections. Hence, the need and use of reverse transcriptase inhibitors are expected to increase in the coming years, which is likely to fuel the market growth across the globe.

Application-Based Insights

Based on application, the global anti-viral therapies market is segmented into HIV, hepatitis, herpes, virus influenza, and other applications. The HIV segment held the largest share of the market in 2021. Further, the hepatitis segment is estimated to register the highest CAGR during the forecast period.

By geography, the global market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

The Asia Pacific anti-viral therapies market is expected to grow at the fastest rate during the forecast period. The market is estimated to grow during the forecast period due to the rising pharmaceutical industry in China, Japan, India, and other Asia Pacific countries. The increasing incidences of viral diseases in the region and growing product developments by the local as well as international market players is likely to favor market growth. Further, China's pharmaceutical industry is among the largest pharmaceutical industry across the globe. The country has shown significant growth in active pharmaceutical ingredient manufacturing, competitiveness, innovations, and final dosage formation. Hence, most multinational companies are showing interest in the Chinese market for drug sales.

Growing efforts by governments of various countries and pharmaceutical and biotech companies to treat COVID-19 patients are likely to propel the growth of the anti-viral therapies market during the forecast period. In the US, the FDA has approved the emergency-use authorization of experimental drugs. Clinical trials of remdesivir, monoclonal antibodies, interferons, ACE inhibitors, and hydroxychloroquine have all been registered in the US. Furthermore, pharmaceutical companies in the country are making tremendous efforts to develop drugs and vaccines for the treatment of COVID-19 patients. In June 2020, scientists from the University of Oxford had been testing existing drugs as therapies for COVID-19 patients. Furthermore, The European Commission in July authorized remdesivir, making it the first approved drug for the treatment of COVID-19 in the European Union.

Company Profiles

A few of the major players operating in the anti-viral therapies market include AbbVie Inc.; Abbott; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc; and Aurobindo Pharma Limited.


RD Image
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
REGIONAL FRAMEWORK
World Geography
Strategic Insights

Have a question?

Analyst

Akshay

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst   Speak to Analyst
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
MARKET PLAYERS
pharmaceuticals
Research Criteria
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Mechanism of Action, and Application

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is anti-viral therapies?

Antiviral therapies is one of the most exciting branches of virology, which involves developing a treatment for viral infections. There are several strategies used to develop antiviral therapy, including direct-acting antivirals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize circulating viruses; drugs that target cellular proteins or processes essential for viral replication.

What are the driving factors for the anti-viral therapies market across the globe?

The factors that are driving growth of the market are growing prevalence of viral diseases, increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials. Moreover, emerging markets is expected to offer lucrative opportunities for the growth of the market.

Who are the major players in the anti-viral therapies market?

The anti-viral therapies market majorly consists of the players such as AbbVie Inc., Abbott, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, AstraZeneca and Aurobindo Pharma Limited amongst others.

The List of Companies - Anti- Viral Therapies Market

  1. AbbVie Inc.
  2. Abbott
  3. F. Hoffmann-La Roche Ltd
  4. Bristol-Myers Squibb Company
  5. Johnson & Johnson Services, Inc.
  6. Merck and Co., Inc.
  7. Gilead Sciences, Inc.
  8. GlaxoSmithKline plc
  9. Aurobindo Pharma
  10. AstraZeneca

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Anti-Viral Therapies Market